Few data are available for ranitidine pharmacokinetics in the first few days of life. Twenty seven newborn infants were treated with intravenous ranitidine because they were vomiting blood, although they had a negative Apt's test. Each infant provided two blood samples at randomly selected times 30-360 minutes after a 2-4 mg/kg intravenous bolus of ranitidine. A single exponential equation for the concentration-time graph was fitted to the mean serum concentrations at different times. From this model the following mean (SD) measurements were derived: elimination half life, 207-1 (19.1) minutes; total volume of distribution, 1-52 (0-91) 1/kg; and total plasma clearance, 5 02 (0.46) ml/kg/min. Assuming that these measurements do not change with different administered doses, regimens can be derived to assist in planning ranitidine treatment in newborn infants. (Arch Dis Child 1993; 68: 602-603) Despite the wide use of ranitidine to treat upper gastrointestinal bleeding from mucosal lesions in the neonatal period or to prevent bleeding in critically ill infants, data about its pharmacokinetics in the first few days of life are not available; dosage regimens are largely empirical and derived from studies conducted in older children or adults. This study was undertaken to explore ranitidine pharmacokinetics in the neonatal period. Informed consent was given by the legal guardians of the patients and approval of the local ethics committee was obtained.
these measurements do not change with different administered doses, regimens can be derived to assist in planning ranitidine treatment in newborn infants. (Arch Dis Child 1993; 68: 602-603) Despite the wide use of ranitidine to treat upper gastrointestinal bleeding from mucosal lesions in the neonatal period or to prevent bleeding in critically ill infants, data about its pharmacokinetics in the first few days of life are not available; dosage regimens are largely empirical and derived from studies conducted in older children or adults. This study was undertaken to explore ranitidine pharmacokinetics in the neonatal period. A single exponential model with three points in the terminal phase of the concentration-time graph was selected y=AXexp(-axt) where y= calculated serum concentration, A=1583-8 (95 4) ng/ml (95% confidence interval (CI) 1338-6 to 1828.9) and a (elimination constant)=0 0033(0O0003) 1min (95% CI 0.0015 to 0.0041).
In the interpretative model, A= administered dose/total volume of distribution (Vd) and a=total plasma clearance (Cl)Nd; this equation then became: y= (doseNd) X (exp (-Cl/Vd X t)). 
